IOC publishes Annual Report 2024: celebrating the Games of a New Era
20 June 2025 - The International Olympic Committee (IOC) today published its 2024…
Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform
May 14, 2025 09:15 ET | Source: Renovaro Inc New Proprietary Target…
Phixius by Nacha Expands Bank Account Validation Coverage With ValidiFI
NEW ORLEANS--(BUSINESS WIRE)--Phixius by Nacha—a secure, peer-to-peer payment information network—announced today that…
Woodside Announces Louisiana LNG Partnership With Stonepeak
HOUSTON--(BUSINESS WIRE)--Woodside has entered into a binding agreement with Stonepeak, a leading…
IRBM Expands Functional Genomics Platform to Strengthen Early Drug Discovery
De-Risking Target Validation with Data-Driven Genomic Insights ROME, April 3, 2025 /PRNewswire/…
AV-Comparatives Launches Groundbreaking EDR Detection Validation Test — Kaspersky Next EDR Expert Achieves Certification in Inaugural Assessment
INNSBRUCK, Austria, March 23, 2025 /PRNewswire/ -- AV-Comparatives, a globally recognized independent…
Faraday Future Announces First Two FX 6 Camouflaged Prototype Mules Set to Depart Shanghai Today with Arrival into the Los Angeles Area in Mid-March
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) (“FF”, “Faraday Future”,…
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.
LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4…
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.
LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4…
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.
LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4…